10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

Rhea-AI Summary

10x Genomics (Nasdaq: TXG) reported that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are licensed from Roche Sequencing Solutions. The jury upheld all three patents as valid and enforceable and awarded 10x Genomics over $4.8 million in damages, based on a 14% royalty rate on Parse’s U.S. sales of Evercode Whole Transcriptome products from February 2021 through June 30, 2026. According to 10x Genomics, it will seek enhanced damages, attorneys’ fees, and a permanent U.S. injunction against further infringement in post-trial proceedings.

Positive

• Jury damages award over $4.8 million to 10x Genomics based on infringing sales from February 2021–June 30, 2026
• Royalty rate of 14% applied by the jury to Parse’s infringing Evercode Whole Transcriptome product sales
• Three patents exclusively licensed to Scale Biosciences found valid and enforceable by the Delaware jury
• Willful infringement finding allows 10x Genomics to seek enhanced damages and attorneys’ fees in post-trial motions

Negative

• None.

Argus Aug 28 session

-1.44% close to close Open Argus

Details

News Market Reaction – QGEN

On Aug 28, the day this news came out, QGEN closed 1.44% below the previous close.

Data tracked by StockTitan Argus for the Aug 28 session.

Key Figures

Damages award: over $4.8 million Royalty rate: 14% Patents infringed: three patents +2 more

Damages award

over $4.8 million

Sales of infringing Evercode Whole Transcriptome products

Royalty rate

14%

Applied to infringing Parse sales

Patents infringed

three patents

Jury found willful infringement

Damages period start

February 2021

Beginning of sales period used for damages

Damages period end

June 30, 2026

End of sales period used for damages

Historical Context

5 past events · Latest: Aug 24

5 events

1. Aug 24

   Leadership appointment

   24h Move

   -5.2%

   Jonathan M. Pratt appointed CEO effective September 1, 2026

2. Aug 10

   FDA clearance

   24h Move

   -2.7%

   QIAstat-Dx received U.S. clearance for bloodstream infection testing

3. Aug 05

   Q2 earnings report

   24h Move

   -0.5%

   QIAGEN exceeded its Q2 outlook while reaffirming full-year guidance

4. Jul 15

   Diagnostic testing update

   24h Move

   +0.7%

   QIAGEN highlighted testing products amid a U.S. Cyclospora outbreak

5. Jul 15

   Earnings date notice

   24h Move

   -0.8%

   QIAGEN scheduled its Q2 2026 results release and webcast

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

patent infringement, royalty rate, permanent injunction, invalidity challenge

4 terms

patent infringement regulatory

"10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences"

Patent infringement occurs when someone makes, uses, sells or imports a product or process that is covered by another party’s patent without permission — like copying a chef’s secret recipe and selling the dish without consent. For investors it matters because alleged infringement can trigger costly lawsuits, damage awards, sales bans or forced licensing, any of which can reduce revenue, increase expenses and hurt a company’s stock value.

royalty rate financial

"The damages award is based on a 14% royalty rate on infringing Parse sales."

A royalty rate is the percentage or fixed fee a company pays the owner of an asset—such as a patent, trademark, mineral right or copyrighted work—each time it sells products or uses that asset. Think of it like rent or a commission the asset owner charges for use; higher rates reduce the user company’s profit on those sales and can materially affect cash flow, margins and valuation, so investors watch them to gauge future profitability and risk.

permanent injunction regulatory

"10x will seek additional awards including enhanced damages and attorneys' fees"

A permanent injunction is a final court order that requires a person or company to stop doing, or to do, a specific act indefinitely. Think of it like a referee issuing a long-term ban or mandate that changes what a business can sell, make, or how it operates; for investors it can alter future revenue, legal costs, asset value and the risk profile of a company, so it can materially affect stock value and investment decisions.

invalidity challenge regulatory

"rejects Parse's invalidity challenge"

A legal claim or proceeding that argues an existing intellectual property right—most commonly a patent or trademark—should be declared invalid because it fails to meet legal requirements like novelty, usefulness, or proper filing. Think of it like challenging the title to a piece of property: if the challenge succeeds, the holder can lose exclusive control, which can change expected future income, competitive position, and legal risk for companies that rely on that intellectual property.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge

PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are exclusively licensed from Roche Sequencing Solutions. The jury also rejected Parse's challenges to the validity of the patents, finding all three patents valid and enforceable.

"I started working on these inventions more than a decade ago and I'm incredibly proud of how they've expanded what's possible with single cell analysis," said Garry Nolan, PhD, co-founder of Scale Biosciences. "Today's verdict is a win for inventors. It affirms that original ideas matter and that strong patent rights are essential to advancing science."

"At Scale Bio, we executed on building high-quality technologies that changed what was possible for scientists," said Giovanna Prout, former CEO of Scale Biosciences. "Part of that was securing and investing in foundational intellectual property to protect our technology, enable further innovation and ensure that technology was respected by others in the industry. This is a critical part of what allows innovative companies to keep pushing science forward."

The jury awarded 10x over $4.8 million in damages for sales of Parse's infringing Evercode Whole Transcriptome products from February 2021 through June 30, 2026. The damages award is based on a 14% royalty rate on infringing Parse sales. In post-trial proceedings, 10x will seek additional awards including enhanced damages and attorneys' fees for Parse's willful infringement, and a permanent injunction stopping further infringement by Parse in the United States.

"The evidence presented at trial shows that Parse made a deliberate and calculated decision to ignore Dr. Nolan's seminal inventions in single cell analysis. The jury heard the evidence and soundly rejected Parse's defenses to find that Parse willfully infringed the patents exclusively licensed to Scale," said Randy Wu, General Counsel of 10x Genomics. "We are pleased with today's verdict, which makes clear that companies cannot simply benefit from the innovation of others and disregard the patent rights protecting them."

The patents adjudicated at trial are U.S. Patent Nos. 10,626,442, 10,982,256, and 11,512,341.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended June 30, 2026 and 10-K for the fiscal year ended December 31, 2025 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-wins-patent-infringement-verdict-against-parse-biosciences-302863074.html

SOURCE 10x Genomics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the August 28, 2026 patent verdict award 10x Genomics (NASDAQ: TXG) against Parse Biosciences?

The jury awarded 10x Genomics over $4.8 million in damages. According to 10x Genomics, this award is based on a 14% royalty rate applied to Parse’s infringing U.S. sales of Evercode Whole Transcriptome products from February 2021 through June 30, 2026.

Which patents did the Delaware jury find Parse Biosciences infringed in the 10x Genomics case (TXG)?

The jury found infringement of three U.S. patents: 10,626,442; 10,982,256; and 11,512,341. According to 10x Genomics, these patents are exclusively licensed to Scale Biosciences from Roche Sequencing Solutions and were all found valid and enforceable in the Delaware trial.

What royalty rate did the jury apply in the 10x Genomics vs. Parse Biosciences patent case?

The jury applied a 14% royalty rate to Parse’s infringing product sales. According to 10x Genomics, this rate was used to calculate more than $4.8 million in damages tied to Evercode Whole Transcriptome sales from February 2021 through June 30, 2026.

What are 10x Genomics’ next legal steps after the Parse Biosciences patent verdict in 2026?

10x Genomics plans to pursue additional post-trial relief following the verdict. According to 10x Genomics, it will seek enhanced damages, attorneys’ fees based on the willfulness finding, and a permanent injunction stopping further infringement by Parse in the United States.

How is Scale Biosciences involved in the 10x Genomics (TXG) patent verdict against Parse Biosciences?

Scale Biosciences holds exclusive licenses to the patents at issue and is part of 10x Genomics. According to 10x Genomics, the infringed patents are exclusively licensed to Scale from Roche Sequencing Solutions, and Scale joined 10x in 2025, linking the IP to 10x’s portfolio.

How is Qiagen (NYSE: QGEN) connected to the 10x Genomics patent verdict involving Parse Biosciences?

Parse Biosciences is now a subsidiary of Qiagen, linking Qiagen to the case through ownership. According to 10x Genomics, the Delaware jury found that Parse’s Evercode Whole Transcriptome products infringed three patents exclusively licensed to Scale Biosciences, with damages awarded to 10x.